In a study examining patient-reported outcomes (PROs) in a real-world, multinational population of patients with gBRCA1/2 m HER2-negative advanced breast cancer, PARPis were associated with an improved quality of life (QoL) across multiple dimensions compared to chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.